() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Category Archives: Recommended Reads

Canbud Distribution Enters into Definitive Agreement to Acquire Molecular Science Corp.

Canbud Distribution Corp. (CSE: CBDX) ("Canbud" or the "Corporation") is pleased to announce that, further to its news release of May 27, 2021, it has entered into a definitive acquisition agreement (the "Acquisition Agreement") with Molecular Science Corp. ("MSC") and 2847719 Ontario Inc. ("Subco"), a wholly-owned subsidiary of Canbud, pursuant to which it agreed to acquire all of the outstanding securities of MSC by way of a three-cornered amalgamation (the "Transaction"). The Transaction is subject to receipt of all necessary regulatory approvals, including, as applicable, approval of the Canadian Securities Exchange ("CSE"), and certain other conditions as described below.
Read more

TRULIEVE ANNOUNCES THE LARGEST US CANNABIS TRANSACTION; ACQUISITION OF HARVEST HEALTH & RECREATION INC., CREATES THE MOST PROFITABLE MULTI-STATE OPERATOR IN THE WORLD’S LARGEST CANNABIS MARKET

Trulieve Cannabis Corp. ("Trulieve" or the "Company") (CSE: TRUL) (OTC: TCNNF) and Harvest Health & Recreation Inc. ("Harvest") (CSE: HARV, OTCQX: HRVSF) are pleased to announce they have entered into a definitive arrangement agreement (the  "Arrangement Agreement") pursuant to which Trulieve will acquire all of the issued and outstanding subordinate voting shares, multiple voting shares and super voting shares (the "Harvest Shares") of Harvest (the "Transaction"). Under the terms of the Arrangement Agreement, shareholders of Harvest (the "Harvest Shareholders") will receive 0.1170 of a subordinate voting share of Trulieve (each whole share, a "Trulieve Share") for each Harvest subordinate voting share (or equivalent) held (the "Exchange Ratio"), representing total consideration of approximately $2.1 billion based on the closing price of the Trulieve Shares on May 7, 2021.
Read more

PharmaTher Files U.S. Patent for Novel Combinations of Psilocybin and FDA Approved Drugs to Treat Neurological Disorders

PharmaTher Inc., (“PharmaTher” or the “Company”), a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTC Pink: PHRRF) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining the potential for novel combinations of psilocybin and U.S. Food and Drug Administration (“FDA”) approved drugs to treat neurological disorders.
Read more